Mohamed Houcem E. Laouar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Mohamed Houcem E. Laouar has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- Elena Vladimirovna Reznik
Pirogov Russian National Research Medical University
3 shared publications - Georgiy N. Golukhov
Pirogov Russian National Research Medical University, Moscow, Russia
2 shared publications - Rodion V. Ponomarev
National Medical Research Center for Hematology
2 shared publications A. A. Duktovskaya
N.I. Pirogov Russian National Research Medical University of the Ministry of Health of the Russia (Pirogov University)
1 shared publication- A. B. Leonova
N.I. Pirogov Russian National Research Medical University of the Ministry of Health of the Russia (Pirogov University)
1 shared publication - A. D. Belyakova
Federal State Budgetary Institution “NMIC of Hematology” of the Ministry of Health of the Russian Federation
1 shared publication
Latest Publications
- 28 August 2026
- Published by Medical Informational Agency Publishers in Clinical Medicine (Russian Journal)
- Vol. 104 (6) , 476-482
Iron accumulation in the heart of a patient with primary hemochromatosis type I (homozygous C282Y mutation of the HFE gene)
Primary hemochromatosis results from pathogenic variants in several genes that can lead to increased iron stores in the body, with excess iron deposited in various organs including the liver, pancreas, and heart. Primary hemochromatosis is associated with homozygosity for the HFE p.Cys282Tyr mutation in 80% of cases. However, rare cases of hemochromatosis (nonHFE hemochromatosis) can be caused by pathogenic variants in other genes (such as HJV, HAMP, TFR2, and SLC40A1). Deposition of excess iron in parenchymal tissues leads to cellular dysfunction and clinical manifestations of the disease. The most commonly aff ected organs are the liver, pancreas, joints, skin, pituitary gland, and heart. Iron-overload cardiomyopathy is systolic or diastolic dysfunction of the heart caused by excess iron deposition, resulting in chronic heart failure. The gold standard for diagnosing primary hemochromatosis is genetic testing, which should be performed in all patients suspected of having this pathology after excluding secondary causes of iron overload. The mainstay of hemochromatosis therapy is therapeutic phlebotomy and iron chelation. The article presents a clinical case of a patient with primary hemochromatosis and a history of very high serum ferritin levels, which led to iron accumulation in the heart.
- 28 August 2026
- Published by Medical Informational Agency Publishers in Clinical Medicine (Russian Journal)
- Vol. 104 (6) , 476-482
Iron accumulation in the heart of a patient with primary hemochromatosis type I (homozygous C282Y mutation of the HFE gene)
Primary hemochromatosis results from pathogenic variants in several genes that can lead to increased iron stores in the body, with excess iron deposited in various organs including the liver, pancreas, and heart. Primary hemochromatosis is associated with homozygosity for the HFE p.Cys282Tyr mutation in 80% of cases. However, rare cases of hemochromatosis (nonHFE hemochromatosis) can be caused by pathogenic variants in other genes (such as HJV, HAMP, TFR2, and SLC40A1). Deposition of excess iron in parenchymal tissues leads to cellular dysfunction and clinical manifestations of the disease. The most commonly aff ected organs are the liver, pancreas, joints, skin, pituitary gland, and heart. Iron-overload cardiomyopathy is systolic or diastolic dysfunction of the heart caused by excess iron deposition, resulting in chronic heart failure. The gold standard for diagnosing primary hemochromatosis is genetic testing, which should be performed in all patients suspected of having this pathology after excluding secondary causes of iron overload. The mainstay of hemochromatosis therapy is therapeutic phlebotomy and iron chelation. The article presents a clinical case of a patient with primary hemochromatosis and a history of very high serum ferritin levels, which led to iron accumulation in the heart.
- 17 May 2026
- Published by Medical Informational Agency Publishers in Clinical Medicine (Russian Journal)
- Vol. 104 (3) , 226-234
Stress-induced cardiomyopathy (takotsubo syndrome) in a patient with primary hemochromatosis
Hemochromatosis is a disease associated with excess iron in the body. Primary (hereditary) hemochromatosis, occurs due to mutations in genes encoding iron metabolism proteins. Elevated serum iron concentrations can lead to iron accumulation in parenchymatous organs and tissues, especially in the liver, pancreas, heart, pituitary gland, and testicles, resulting in the development of fibrosis and failure of these organs. Diagnosis of hereditary hemochromatosis includes genetic testing, evaluation of serum iron metabolism parameters, and imaging data. The article describes a case of Takotsubo syndrome development in a patient with primary hemochromatosis. Takotsubo syndrome is characterized by transient regional systolic dysfunction, dilation and edema of the apical and/or middle segments of the left ventricle (LV), in the absence of coronary artery obstruction during coronary angiography. At the age of 49, an examination revealed an increase in ferritin, genetic testing revealed a homozygous mutation C282Y in the HFE gene, hereditary hemochromatosis was diagnosed, erythrocytapheresis was performed, and she is being monitored by a hematologist. At the age of 56, she was hospitalized with suspected acute coronary syndrome with ST segment elevation, an increase in troponin I levels to 1.8 ng/ml. Coronary angiography did not reveal any hemodynamically significant stenosis. Echocardiography revealed hypoand dyskinesis of the apical segments, a decrease in the LV ejection fraction to 45%. Dynamically, normalization of the troponin level, ECG, and restoration of LV function were noted. Takotsubo syndrome was diagnosed in a patient with primary hemochromatosis, the combination of which was not mentioned in previously published works.
- 17 May 2026
- Published by Medical Informational Agency Publishers in Clinical Medicine (Russian Journal)
- Vol. 104 (3) , 226-234
Stress-induced cardiomyopathy (takotsubo syndrome) in a patient with primary hemochromatosis
Hemochromatosis is a disease associated with excess iron in the body. Primary (hereditary) hemochromatosis, occurs due to mutations in genes encoding iron metabolism proteins. Elevated serum iron concentrations can lead to iron accumulation in parenchymatous organs and tissues, especially in the liver, pancreas, heart, pituitary gland, and testicles, resulting in the development of fibrosis and failure of these organs. Diagnosis of hereditary hemochromatosis includes genetic testing, evaluation of serum iron metabolism parameters, and imaging data. The article describes a case of Takotsubo syndrome development in a patient with primary hemochromatosis. Takotsubo syndrome is characterized by transient regional systolic dysfunction, dilation and edema of the apical and/or middle segments of the left ventricle (LV), in the absence of coronary artery obstruction during coronary angiography. At the age of 49, an examination revealed an increase in ferritin, genetic testing revealed a homozygous mutation C282Y in the HFE gene, hereditary hemochromatosis was diagnosed, erythrocytapheresis was performed, and she is being monitored by a hematologist. At the age of 56, she was hospitalized with suspected acute coronary syndrome with ST segment elevation, an increase in troponin I levels to 1.8 ng/ml. Coronary angiography did not reveal any hemodynamically significant stenosis. Echocardiography revealed hypoand dyskinesis of the apical segments, a decrease in the LV ejection fraction to 45%. Dynamically, normalization of the troponin level, ECG, and restoration of LV function were noted. Takotsubo syndrome was diagnosed in a patient with primary hemochromatosis, the combination of which was not mentioned in previously published works.
- Open Access
- 26 November 2025
- Published by Intermedservice Ltd in Eurasian heart journal
- No. 4,p. 74-80
Characteristics of the structural and functional state of the cardiovascular system in carriers of the HFE gene mutations
Objectives. To characterize the state of the cardiovascular system in patients carrying the HFE gene mutations in the Russian Federation. Materials and methods. An evaluation of 39 cases of HFE gene mutations confirmed by biochemical and genetic methods was carried out. Results. When analyzing the medical records of 39 patients with HFE gene mutations, changes in the structural and functional state of the cardiovascular system were detected in 20 (51.3%) patients. There was a history of arterial hypertension in 11 (28.21%) patients. Acute cerebrovascular accident was indicated in the anamnesis in 2 (5.13%) patients. A history of myocardial infarction was detected in 3 (7.69%) patients. Heart failure of non-ischemic genesis was diagnosed in 5 (12.82%) patients. In 14 (35.9%) patients in the form of atrioventricular block, left bundle branch block, right bundle branch block, intraventricular conduction disturbances, shortening of the PQ interval and prolongation of the QT interval, in 1 (2.56%) patient a paroxysmal form of atrial fibrillation was noted. Conclusion. Half patients with HFE gene mutations had various changes in the cardiovascular system. In this regard, patients with cardiac pathology of unclear etiology require screening for timely diagnosis of hemochromatosis and joint management of patients with confirmed hemochromatosis by hematologists, cardiologists and hepatologists to prevent cardiovascular complications.
- 26 November 2025
- Published by Intermedservice Ltd in Eurasian heart journal
- No. 4,p. 74-80
Open AccessCharacteristics of the structural and functional state of the cardiovascular system in carriers of the HFE gene mutations
Objectives. To characterize the state of the cardiovascular system in patients carrying the HFE gene mutations in the Russian Federation. Materials and methods. An evaluation of 39 cases of HFE gene mutations confirmed by biochemical and genetic methods was carried out. Results. When analyzing the medical records of 39 patients with HFE gene mutations, changes in the structural and functional state of the cardiovascular system were detected in 20 (51.3%) patients. There was a history of arterial hypertension in 11 (28.21%) patients. Acute cerebrovascular accident was indicated in the anamnesis in 2 (5.13%) patients. A history of myocardial infarction was detected in 3 (7.69%) patients. Heart failure of non-ischemic genesis was diagnosed in 5 (12.82%) patients. In 14 (35.9%) patients in the form of atrioventricular block, left bundle branch block, right bundle branch block, intraventricular conduction disturbances, shortening of the PQ interval and prolongation of the QT interval, in 1 (2.56%) patient a paroxysmal form of atrial fibrillation was noted. Conclusion. Half patients with HFE gene mutations had various changes in the cardiovascular system. In this regard, patients with cardiac pathology of unclear etiology require screening for timely diagnosis of hemochromatosis and joint management of patients with confirmed hemochromatosis by hematologists, cardiologists and hepatologists to prevent cardiovascular complications.
- Open Access
- 27 November 2024
- Published by Synapse, LLC in The Russian Archives of Internal Medicine
- Vol. 14 (6) , 442-456
Hemochromatosis and Heart Involvement
Hemochromatosis is a life-threatening condition if left untreated, that is caused by excess iron in the body. It can be primary (hereditary) hemochromatosis, resulting from genes mutations, and secondary (acquired) as a result of excessive intake of iron from food or drugs, liver diseases or repeated blood transfusions. Deposition of excess iron in parenchymal tissues leads to cellular dysfunction and clinical manifestations of the disease. The liver, pancreas, joints, skin, pituitary gland and heart are most often affected. Cardiac hemochromatosis is an important and potentially preventable cause of heart failure. Initially, diastolic dysfunction and arrhythmias develop, at later stages a picture of dilated cardiomyopathy can appear. Signs of heart damage in hemochromatosis can be detected using complex 2D and Doppler echocardiography, cardiac MRI with T2* relaxation time measurement and other diagnostic methods. Genetic testing is the gold standard for diagnosing hemochromatosis and should be performed after secondary causes of iron overload have been excluded. The basis of therapy is therapeutic phlebotomy and iron chelation. Median survival is less than a year in untreated patients with severe heart failure caused by hemochromatosis. However, with early and aggressive treatment, survival approaches that of patients with heart failure of other etiologies.
- 27 November 2024
- Published by Synapse, LLC in The Russian Archives of Internal Medicine
- Vol. 14 (6) , 442-456
Open AccessHemochromatosis and Heart Involvement
Hemochromatosis is a life-threatening condition if left untreated, that is caused by excess iron in the body. It can be primary (hereditary) hemochromatosis, resulting from genes mutations, and secondary (acquired) as a result of excessive intake of iron from food or drugs, liver diseases or repeated blood transfusions. Deposition of excess iron in parenchymal tissues leads to cellular dysfunction and clinical manifestations of the disease. The liver, pancreas, joints, skin, pituitary gland and heart are most often affected. Cardiac hemochromatosis is an important and potentially preventable cause of heart failure. Initially, diastolic dysfunction and arrhythmias develop, at later stages a picture of dilated cardiomyopathy can appear. Signs of heart damage in hemochromatosis can be detected using complex 2D and Doppler echocardiography, cardiac MRI with T2* relaxation time measurement and other diagnostic methods. Genetic testing is the gold standard for diagnosing hemochromatosis and should be performed after secondary causes of iron overload have been excluded. The basis of therapy is therapeutic phlebotomy and iron chelation. Median survival is less than a year in untreated patients with severe heart failure caused by hemochromatosis. However, with early and aggressive treatment, survival approaches that of patients with heart failure of other etiologies.